32. Brossier F, Guindo D, Pham A, Reibel F, Sougakoff F, Veziris N, et al. Performance of the new version (2.0) of the GenoTypeMTBDRsl test for detection of resistance to secondline drugs in multidrug-resistant Mycobacterium tuberculosis complex strains. J Clin Microbiol. 2016;54:1573–80. 33. World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line antituberculosis drugs. Policy guidance. World Health Organization Document. 2016; WHO/HTM/TB/2016.07 1-43. 34. Iseman MD. Treatment of multidrug-resistant tuberculosis. N Engl J Med. 1993;329:784–91. 35. Fox W, Ellard GA, Mitchison DA. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis. 1999;3 Suppl 2:S231–79. 36. Caminero JA, Matteelli A, Lange C. Chapter 12. Treatment of TB. Eur Respir Monogr. 2012;58:154–66. 37. Caminero JA, Sotgiu G, Zumla A, Migliori GB. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet Infect Dis. 2010;10:621–9. 38. Caminero JA, Scardigli A. Classification of anti-TB drugs: A new potential proposal based on the most recent evidence. Eur Respir J. 2015;46:887–93. 39. Falzon D, Gandhi N, Migliori GB, Sotgiu G, Cox HS, Holtz TH, et al. Resistance to fluoroquinolones and secondline injectable drugs: Impact on multidrug-resistant TB outcomes. Eur Respir J. 2013;42:156–68. 40. Johnston JC, Shahidi NC, Sadatsafavi M, FitzGerald JM. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS ONE. 2009;4:e6914.
38